NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44)

Post Date

February 17th 2012

Application Due Date

June 19th 2014

Funding Opportunity Number

RFA-HL-13-016

CFDA Number(s)

93.233
93.837
93.838

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

Small Businesses

Funding

• Estimated Total Funding:

  $5000000

• Award Range:

  $None - $None

Grant Description

The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR Phase II projects to the commercialization stage by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-016.html